50 results about "Gene transcript" patented technology

Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and non-LTR retrotransposon elements.

The present disclosure relates to the field of genetic engineering technology, and more specifically, to a targeting ligand. The targeting ligand provided herein forms a siRNA conjugate with a specific small interfering RNA sequence, which targets ANGPTL3 and degrades ANGPTL3 gene transcripts in cells, thereby reducing ANGPTL3 protein expression. Therefore, the siRNA conjugate formed with the targeting ligand provided herein can be used to prevent and / or treat dyslipidemia.

The present invention provides systems and methods for cell free RNA sequencing. Targeted sequencing can be performed using a set of gene transcripts that are rare abundance in a population of cell free nucleic acid control samples.

The invention discloses a saccharomyces cerevisiae microbiome RNA (Ribonucleic Acid) sequencing data analysis method based on long read length sequencing, which is characterized in that the structure of a gene is updated and optimized by efficiently comparing reference genome data and identifying a new transcript and a new gene transcript of a known gene, so that complete data is provided for analyzing a yeast mRNA (Messenger Ribonucleic Acid) and ncRNA (Non-coding Ribonucleic Acid) structure; and the analysis accuracy and effectiveness are improved.

The application discloses a molecular marker, a primer, a detection method and application related to pig muscle fiber, rib number and back fat thickness, and relates to the technical field of molecular markers. The molecular marker is located in a MYLPF gene, and a sequence of the molecular marker is shown as SEQ ID NO: 4. The sequence is located at a first exon of a 202 transcript of the MYLPF gene, and is used for detecting SNP site mutation. The application determines a cause mutation affecting the circumference, area of pig muscle fiber, rib number and average back fat thickness by using a MYLPF gene promoter constructed to replace a double luciferase reporter vector. A specific primer is designed on the mutation site of the promoter and amplification is performed. The site is detected for polymorphism by using a restriction endonuclease NlaIII. According to the result of the polymorphism detection, differences in the circumference, area of muscle fiber, rib number and average back fat thickness among pig individuals are distinguished, and a large population scale sampling and determination is not needed.

An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation of one or more of the following proteins encoded by a corresponding gene transcript or portion thereof: S100A8; S100A9; and / or IL1RL2.

The present disclosure generally relates to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504 and conjugates thereof. The present invention also relates to antisense oligonucleotides that modulates mRNA productive transcript, stability and / or translation of OPA1 gene transcript or part thereof linked to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504.

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.

The present invention relates to antisense oligonucleotides (ASO) for use in treating, preventing, or ameliorating the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance, and obesity, Rater Syndrome, and cancer. Specifically, a thiomorpholino-containing ASO targets a protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript and induces exon skipping (including exon 2) of the transcript during RNA processing, thereby inhibiting expression of the protein tyrosine phosphatase-1B (PTP1B) protein.

The present invention relates to the field of diseases caused by high LDL-C and / or fibrinogen levels, such as cardiovascular diseases. The invention relates to oligonucleotides for RNA (Ribonucleic Acid) editing technology. The oligonucleotides are used for deamination of target adenosine nucleotides, such as 1055th adenosine, in human B4GALT1 gene transcripts.

Provided herein are altered cell lines comprising a suspension cell line adapted from an adherent cell line having a different expression profile from a corresponding non-altered adherent cell line, methods for generating altered cell lines, and methods of characterizing altered expression profiles for a gene, a transcript, or a protein in an altered cell line.

The present invention relates to the field of genetic engineering technology, and particularly to a method for constructing a mouse model with specific knockout of the Osgep gene in pancreatic islet β cells and its application. The construction method includes the following steps: 1) Determine the knockout region as the exon 2 and exon 3 regions according to the structure of the Osgep gene. The CDS sequence of the Osgep gene transcript is shown in SEQ ID NO.1. Design a gene fragment with flox sites connected at both ends and containing the sequence of the knockout region, and insert this fragment into a plasmid; 2) Design sgRNA according to the upstream sequence and downstream sequence of the knockout region; 3) Mix the sgRNA, Cas9 enzyme and plasmid, and inject them together into the cytoplasm of mouse fertilized eggs to construct edited mouse fertilized eggs and produce F0 generation mice. The present invention discovers through research that Osgep knockout mice can be used for the research of diabetes, and the Osgep gene can play a role in treating diabetic mice.

This invention discloses a method utilizing Breast Milk A method for identifying the red coat color phenotype in cattle using an 8403 bp gene sequence. Analysis of third-generation sequencing data from domestic cattle samples with different coat color phenotypes identified, for the first time, a gene significantly associated with the red coat color phenotype. Breast Milk An 8403bp structural variation in the gene sequence overlaps with a LINE-1 transposon, leading to... Breast Milk Gene transcripts produce different mRNA isoforms. This invention achieves the detection of bovine mRNA using two pairs of primers. Breast Milk Gene detection and accurate genotyping can be performed, enabling marker-assisted selection of the red coat color trait in cattle at the DNA level.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The invention relates to the proteins Agrin, Zyxin, Synaptotagmin-5, and combinations thereof, as well as the gene transcripts form the corresponding genes, as biomarkers of a hypoxic-ischemic encephalopathy (HIE).

The present invention relates to a high-precision single-cell clustering method and system based on marker genes and ensemble learning, including: Step 1: Feature extraction; using a feature extraction algorithm and a dimensionality reduction algorithm to reduce the dimensionality of the cell expression matrix and extract cell features; each element in the cell expression matrix corresponds to the expression of a gene / transcript in a given cell; Step 2: Inner-layer clustering; the expression matrix after feature extraction is used as input and applied to the inner-layer clustering method; the inner-layer clustering method includes the single-cell clustering method SNN-Cliq and the self-organizing mapping method SOM of deep learning; Step 3: Calculate the consensus matrix; use the clustering-based similarity partitioning algorithm CSPA to calculate the consensus matrix C; Step 4: Consensus clustering; construct a graph c according to the consensus matrix C, where the nodes Node in the graph c represent cells, and the weight edge of the edge represents the probability that two nodes are in the same partition.

The present invention relates generally to methods and diagnostic applications for treating ulcerative colitis. More specifically, the methods and diagnostic applications of the invention relate to the expression profiles of certain gene transcripts in ulcerative colitis patients and the use of the expression profiles of these gene transcripts for therapy and / or diagnosis in subpopulations of patients suffering from ulcerative colitis.

An isolated or purified antisense oligomer which has a modified backbone structure for modifying pre-mRNA splicing in the PPIB gene transcript or part thereof.

The present disclosure relates to the field of diseases caused by iron overload, such as homeostatic iron regulatory protein (HFE) hemochromatosis. The present disclosure provides oligonucleotides for RNA editing technology that target and deaminate the c.845G>A nucleotide in the transcript of the p.Cys282Tyr (C282Y) mutant human HFE gene, reducing iron overload, particularly in the liver.

An isolated or purified antisense oligomer and compositions and mixtures for modifying pre-messenger RNA (pre mRNA) splicing or mRNA translation in a SOST gene transcript or part thereof to induce down regulation of functional SOST protein production.

The present invention relates to antisense oligonucleotides (ASOs) used to treat, prevent, or mitigate the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance and obesity, Rett syndrome, and cancer. Specifically, thiomorpholino-containing ASOs target the protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript during RNA processing and induce exon skipping (including exon 2), thereby inhibiting the expression of protein tyrosine phosphatase-1B (PTP1B) protein.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing or mRNA translation in one or more of the following proteins encoded by the respective gene transcript or part thereof LEPROT; and / or LEPROTL1 which has a modified backbone structure, wherein the antisense oligomer induces downregulation of the production of functional LEPROT and / or LEPROTL1 protein.

The present invention relates to a set of gene transcripts (A) isolated from a set of genes consisting of gene subset (1) consisting of ADM, AXL, BIRC5, CDV3, CRIM1, CTGF, CYR61, FSTL1, GADD45A, KRT8, LMNB2, MATN2, PKP4, RND3, RPS24, SEC14L1, SGK1, SLC25A3, SLC3A2, TNFRSF12A, TPM1, TPX2, and TUBB6; and an isolated set of genes (B) consisting of at least one gene transcript from gene subset (2) consisting of CTSB, FTH1, SQSTM1, TCF25, and UBC, or from a set of genes consisting of DLC1, AKAP2, CANX, SAFB2, EIF4H, NDUFS5, SEPT9, and EIF4A1, as well as their use in a diagnostic method for TEAD-activated cancer.

An isolated or purified antisense oligomer for modulating mRNA translation of the OPA1 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.

The invention relates to an isolated set of gene transcripts (A) from a set of genes consisting of a subset of genes (1) consisting of ADM, AXL, BIRC5, CDV3, CRIM1, CTGF, CYR61, FSTL1, GADD45A, KRT8, LMNB2, MATN2, PKP4, RND3, RPS24, SEC14L1, SGK1, SLC25A3, SLC3A2, TNFRSF12A, TPM1, TPX2, TUBB6 and of a subset of genes (2) consisting of CTSB, FTH1, SQSTM1, TCF25, UBC, or an isolated set of genes (B) consisting of at least one gene transcript from a set of genes consisting of DLC1, AKAP2, CANX, SAFB2, EIF4H, NDUFS5, SEPT9, and EIF4A1, and their use in diagnostic methods for TEAD-active cancer.

The invention provides a construction method of a Keshan disease rat model, and belongs to the field of animal model construction. The construction method of the rat model comprises the following steps: constructing a rat of which the 874th basic group G of the SEPHS2 gene is deleted; the SEPHS2 gene is characterized in that the transcript number of the SEPHS2 gene is ENSRNOTT00000074114.3, and the SEPHS2 gene has a nucleotide sequence shown in The research finds that c.874delG mutation of the SEPHS2 gene is obviously related to Keshan disease in cardiomyopathy. After the 874th basic group G of the SEPHS2 gene of the SD rat is deleted, the obtained SD rat has dilated cardiomyopathy change with obvious systolic failure, which is a typical Keshan disease myocardial damage expression. Therefore, a cardiomyopathy model, especially a Keshan disease model, can be prepared by performing c.874delG mutation on the SEPHS2 gene of the SD rat, a model basis can be provided for cardiomyopathy research, especially Keshan disease research, and a good application prospect is achieved.